Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor-Reference-Cited by-同舟云学术

Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor

Published:2023-01 Issue:1 Volume:22 Page:119-123
ISSN:1569-1993
Container-title:Journal of Cystic Fibrosis
language:en
Short-container-title:Journal of Cystic Fibrosis

Author:

Fajac Isabelle^ORCID,Daines Cori,Durieu Isabelle^ORCID,Goralski Jennifer L.^ORCID,Heijerman Harry,Knoop Christiane,Majoor Christof,Bruinsma Bote G.,Moskowitz Samuel,Prieto-Centurion Valentin,Van Brunt Kate,Zhang Yaohua^ORCID,Quittner Alexandra

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Reference15 articles.

1. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele;Middleton;N Engl J Med,2019

2. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial;Heijerman;Lancet,2019

3. Vertex Pharmaceuticals Inc. TRIKAFTA® (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets), co-packaged for oral use. Summary of product characteristics. 2019.

4. Vertex Pharmaceuticals Inc. Trikafta® (elexacaftor/tezacaftor/ivacaftor) [package insert]. Boston, MA. Revised 10/2021.

5. European Pharmaceutical Review. Kaftrio® with ivacaftor approved by EC to treat children with cystic fibrosis. 2022.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Disability Critique of the Comparative View;The American Journal of Bioethics;2024-08-02

2. Exploring the complexity of cystic fibrosis (CF) and psychosocial wellbeing in the 2020s: Current and future challenges;Paediatric Respiratory Reviews;2024-08

3. Wellness in the modulator era: An observational study of the impact of CFTR modulator therapy on the well-being of people with cystic fibrosis;Journal of Cystic Fibrosis;2024-07

4. Validation of the Integrated Palliative Care Outcome Scale (IPOS) in adults with cystic fibrosis;Pediatric Pulmonology;2024-06-27

5. Highly effective cystic fibrosis transmembrane conductance (regulator) modulator therapy: shifting the curve for most while leaving some further behind;Current Opinion in Pediatrics;2024-02-15